13F Holdings
中文EN

RIGL RIGEL PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1034842 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.2%
TTM net income YoY171.1%
TTM EPS YoY159.6%
Revenue 3-yr CAGR29.6%
Net income 3-yr CAGR—

Margins

Gross margin89.6%
Operating margin26.3%
Net margin106.6%
FCF margin—
EBITDA margin27.6%

Returns

ROE109.2%
ROA80.2%
ROIC (approx.)28.7%
Asset turnover0.75x

Leverage & solvency

Liabilities / assets15.0%
Debt / equity0.00x
Current ratio2.39x
Interest coverage18.17x

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio56.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$294.28M$179.28M$116.88M$120.24M$149.24M
Cost of revenue$19.62M$18.65M$7.11M$1.75M$1.08M
Gross profit$274.66M$160.63M$109.77M$118.49M$148.15M
R&D expense$33.30M$23.38M$24.52M$60.27M$65.24M
SG&A expense$115.90M$113.06M$105.74M$112.45M$91.89M
Operating income$125.47M$24.19M-$20.49M-$55.55M-$12.50M
Interest expense$7.32M$7.92M$6.87M$3.71M$4.86M
Pretax income$121.83M$18.37M-$25.09M-$58.57M-$17.31M
Income tax-$245.20M$881,000$0—$605,000
Net income$367.02M$17.48M-$25.09M-$58.57M-$17.91M
EBITDA$127.88M$26.42M-$19.25M-$54.55M-$11.33M
EPS (basic)20.400.99-1.44-3.44-0.11
EPS (diluted)19.480.99-1.44-3.44-0.11
Weighted avg. shares (diluted)18.84M17.69M17.40M17.05M170.49M
Balance sheet
Cash & equivalents$40.58M$56.75M$32.79M$24.46M$18.89M
Short-term investments$114.38M$20.57M$24.15M$33.75M$106.08M
Receivables$51.76M$41.62M$30.55M$40.32M$15.47M
Inventory$11.51M$6.00M$5.52M$9.12M$6.62M
Current assets$240.17M$135.10M$99.27M$115.90M$154.47M
PP&E, net$30,000$92,000$165,000$857,000$2.18M
Intangibles$24.75M$27.10M$13.88M$14.95M—
Total assets$513.59M$163.98M$117.22M$134.28M$167.33M
Current liabilities$99.24M$63.30M$53.27M$65.21M$63.55M
Long-term debt$52.50M$60.00M$60.00M$40.00M$20.00M
Total debt$52.50M$60.00M$60.00M$40.00M$20.00M
Total liabilities$122.11M$160.69M$145.87M$147.90M$136.95M
Shareholders' equity$391.48M$3.29M-$28.64M-$13.62M$30.37M
Net debt$11.92M$3.25M$27.21M$15.54M$1.11M
Shares outstanding18.31M17.71M17.48M173.40M171.60M
Cash flow statement
Operating cash flow$75.66M$31.47M-$5.74M-$73.76M$5.88M
Capital expenditure———$450,000$627,000
Free cash flow———-$74.21M$5.25M
Investing cash flow-$92.36M$4.13M-$4.30M$72.78M-$80.04M
Financing cash flow$601,000-$11.64M$18.37M$6.55M$62.67M
Depreciation & amortization$2.42M$2.23M$1.24M$998,000$1.16M
Stock-based compensation$12.71M$12.39M$8.81M$12.38M$9.49M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.